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Inhibition of the potassium channels TREK-1 by spadin (SPA) is currently thought to be a promising therapeutic target for the
treatment of depression. Since these channels are expressed in pancreatic 𝛽-cells, we investigated their role in the control of
insulin secretion and glucose homeostasis. In this study, we confirmed the expression of TREK-1 channels in the insulin secreting
MIN6-B1 𝛽-cell line and in mouse islets. We found that their blockade by SPA potentiated insulin secretion induced by potassium
chloride dependent membrane depolarization. Inhibition of TREK-1 by SPA induced a decrease of the resting membrane potential
(Δ𝑉m ∼ 12mV) and increased the cytosolic calcium concentration. In mice, administration of SPA enhanced the plasma insulin
level stimulated by glucose, confirming its secretagogue effect observed in vitro. Taken together, this work identifies SPA as a novel
potential pharmacological agent able to control insulin secretion and glucose homeostasis.
1. Introduction
Insulin secretion by pancreatic 𝛽-cells is critical for glu-
cose homeostasis. Glucose-induced insulin secretion relies
on potassium (K+) current-dependent plasma membrane
depolarization [1, 2]. Indeed high glucose concentration
causes the closure of the ATP-sensitive K+ channel (KATP
channel) preventing potassium efflux and leads to 𝛽-cell
membrane depolarization [3–5]. As a consequence, the
voltage-dependent calcium channels open, thus allowing cal-
cium influx responsible for the fusion of insulin-containing
granules to finally release insulin into the bloodstream [6].
The search for innovative therapeutic strategies improving
the 𝛽-cell function is a key issue for the treatment of
diabetes. The first oral antidiabetic agents, metformin and
sulfonylureas, were developed in the 1950s and continue
to be used effectively. Since 2008, two other very promis-
ing therapeutic classes have been placed on the market:
dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like
peptide 1 (GLP-1) analogues to promote insulin secretion
without the risk of hypoglycemia. These two drug therapies
take advantage of the incretin effect which is a decrease
in blood glucose levels. Incretins promote an increase in
the amount of insulin released from islets of Langerhans
after a meal [7, 8]. Sulfonylureas stimulate insulin secretion
by selectively inhibiting 𝛽-cell KATP channels [9]. Beside
inducing intracellular signaling, GLP-1 also regulates glucose
stimulated insulin secretion by the changes in membrane
potential [10].
In pancreatic 𝛽-cells, it is thought that the two-pore
potassium channels (K
2
P) participate in regulating cell
membrane potential [11–13]. Among K
2
P channels, TREK-
1, TREK-2, and TRAAK belong to a subfamily of channels
that are opened by mechanical and chemical stimuli [14–
16]. TREK-1, the first mechanosensitive K+ channel to be
identified [17], is activated by polyunsaturated fatty acids and
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volatile anesthetics [15, 16]. TREK-1 is efficiently inhibited
through an intracellular increase of cAMP that leads to the
protein kinase A (PKA) activation.Therefore, PKA phospho-
rylates the serine 333 in the cytoplasmic C-terminal region
of the channel [18, 19]. This inhibitory effect is also observed
after agonist stimulation of the𝛽-adrenergic receptors known
to increase intracellular cAMP contents [20]. Incretin hor-
mones like GLP1 and gastric inhibitory polypeptide (GIP)
are also able to increase cAMP by activation of PKA [21].
The role of incretins in insulin secretion can therefore be the
consequence of both an increase of cAMP and the activation
of the phosphorylation of key proteins involved in regulation
of insulin exocytosis [22].
Recently, we identified a peptide named spadin (SPA), a
partial sequence of the propeptide (PE) released during the
maturation of sortilin, as a new class of highly effective and
fast acting antidepressants (AD). Sortilin is a class 1 receptor
involved in the sorting of several transmembrane proteins
including TREK-1 [23]. The AD action of SPA is triggered
through the blockade of the TREK-1 channel activity. Since
we previously observed that TREK-1 was expressed in the
pancreatic 𝛽-cell line 𝛽-TC3 [23], we wondered whether
TREK-1 and SPA play a physiological role in the regulation
of insulin secretion by maintaining the membrane potential
of pancreatic cells. In the present work, we demonstrate that
SPA by specifically blocking TREK-1 channels depolarizes
pancreatic 𝛽-cell membranes, increases Ca2+ influx, and
contributes to insulin secretion.
2. Materials and Methods
2.1. Animals for In Vivo Experiments. All experiments were
performed according to policies on the care and use of
laboratory animals of European Community Legislation.The
local Ethics Committee approved the experiments (protocol
number 00893.02).
All efforts were made to minimize animal suffering and
reduce the number of animals used.AdultmaleC57/Bl6mice,
weighing 24–28 g (8–10 weeks old), were used in this study.
The animals housed under controlled laboratory conditions
with a 12 h dark-light cycle, a temperature of 21 ± 2∘C, and
a humidity of 60–70% for at least one week prior to drug
treatment. Mice had free access to standard rodent diet and
tap water.
2.2. Cell Culture. Mouse insulin secreting MIN6-B1 cells
(passages 35–45) were cultured at 37∘C in a humidified atmo-
sphere containing 5%CO
2
in DMEMmedium supplemented
with 5% foetal calf serum, 1mM sodium pyruvate, 2mM glu-
tamate, 50mM 2-mercaptoethanol, 100 units/ml penicillin,
and 100mg/ml streptomycin. For Fura-2AM experiments,
cells were plated at a density of 1.5× 105/ml, onto 25mmpoly-
D Lysine-coated glass coverslips. For the electrophysiological
experiments MIN6-B1 cells were seeded at a density of
20,000 cells/35mm dishes. Then, cell membrane potential
measurements were recorded after 2–6 days of culture.
2.3.Whole Cell Patch ClampRecordings andMembrane Poten-
tial Measurements. Whole cell patch clamp recordings were
performed in MIN6-B1 cells in a bath solution containing
a cocktail of K+ channel blockers to record specifically the
TREK-1 current. This solution contains 10mM tetraethyl
ammonium (TEA), 3mM 4-aminopyridine (4-AP), 50 nM
charybdotoxin, 10mM glibenclamide (Glib), and 100 nM
apamin.
Membrane potentials were measured in MIN6-B1 cells
incubated during 45min in control conditions in the pres-
ence of SPA (1𝜇M) or Glib (10 𝜇M) or both. Each experi-
mental group was tested in the presence of glucose (2mM
or 10mM). After the incubation period, cells were patched
and membrane potentials were immediately measured using
the whole cell patch clamp technique [24]. Each membrane
potential was evaluated by using a RK 400 patch clamp
amplifier (Axon Instruments, USA), low-pass filtered at
3 kHz and digitized at 10 kHz using a 12-bit analogue-to-
digital converter Digidata (1322 series, Axon Instruments,
USA). Patch clamp pipettes were pulled using vertical puller
(PC-10, Narishige) from borosilicate glass capillaries and had
a resistance of 3–5MΩ. The bath solution contained (in mM)
150 NaCl, 5 KCl, 3 MgCl
2
, 1 CaCl
2
, and 10 HEPES adjusted
to pH 7.4 with NaOH. The pipette solution contained (in
mM) 155 KCl, 3 MgCl
2
, 5 EGTA, and 10 HEPES adjusted to
pH 7.2 with KOH. All experiments were performed at room
temperature (21-22∘C).Data acquisitionwas carried out using
a microcomputer (Dell Pentium) witch used commercial
software and hardware (pClamp 8.2). All values ofmembrane
potentials are expressed in mV as mean ± standard error of
the mean (SEM).
2.4. Measurement of Cytosolic Calcium Concentrations. The
cytosolic calcium variations were measured using the Fura-
2AM loading protocol as previously described [25]. Loaded
cells were visualized under an inverted epi-fluorescence
microscope (AxioObserver, Carl Zeiss, France) using a Fluar
40x/1.3 oil immersion objective. The intracellular Fura-
2AM was sequentially excited at 340 and 380 nm with a
Xenon lamp through a high-speed multifilter wheel. For
each excitation wavelength, the fluorescence emission was
discriminated by the same 400 LP dichroic mirror and a
510/40 bandpass filter. Fluorescence images were acquired
every 10 sec on an EMCCD camera (Cascade 512, Roper
Scientific, Evry, France). Calcium image analyses were made
using MetaMorph, MetaFluor (Universal Imaging). Fura-2
fluorescence intensities were expressed as changes relative to
the initial fluorescence ratio (F340/380).
2.5. Islets Preparation. Mouse islets were isolated by hand-
picking after collagenase digestion of pancreas as described
previously [26] and were maintained overnight in DMEM
supplemented with 10% FCS, 10mM HEPES, pH 7.4,
1mMsodiumpyruvate, 100 units/ml penicillin-streptomycin,
50 𝜇M 𝛽-mercaptoethanol, and 11mM glucose.
2.6. Measurement of Insulin Secretion and Cellular Content.
For insulin secretion and cellular content, MIN6-B1 cells (5
× 105 per well) or isolated pancreatic islets (20 islets per well)
were incubated with 0.1 𝜇MSPA for 45min at 37∘C in control
conditions (2.8mM glucose, 5mM KCl) or in stimulating
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conditions (30mM KCl and 16.7mM glucose). The amount
of insulin was measured using an ELISA kit (Mercodia) as
already described [27].
2.7. Western Blot Analysis. Solubilized proteins were sepa-
rated on SDS-PAGE (10% acrylamide) and then transferred
to a nitrocellulosemembrane that was probed simultaneously
with the following primary antibody: a mouse monoclonal
sortilin (1 : 1000, BD Transduction Laboratories) and a rabbit
polyclonal TREK-1 (1 : 1000, Millipore).
2.8. Immunocytochemistry. MIN6-B1 cells were plated on
glass coverslips coated with 2mg/mL poly-L-Lysine. Cells
were preincubated for 10min in Phosphate-Buffered Saline
(PBS) and then fixed for 20min with 4% paraformaldehyde
in PBS at room temperature. Coverslips were rinsed twice
with PBS and incubated with 50mM NH
4
Cl in PBS for
10min to quench excess of free aldehyde groups. After
incubation for 20min in PBS containing 3% Horse Serum
(HS) and 0.1% Triton X100, cells were incubated with a
rabbit polyclonal anti-TREK1 (1/200, Millipore #AB5860) or
a mouse monoclonal anti-chromogranin (1/400, Santa Cruz)
for 2 h at room temperature in PBS containing 0.5% HS and
0.1% Triton-X100. Cells were rinsed three times in PBS and
incubated for 45min at room temperature with a Texas-Red-
conjugated donkey anti-rabbit antibody (1/400, Invitrogen)
or a FITC-conjugated donkey anti-mouse antibody (1/400,
Invitrogen) in PBS containing 0.5% HS and 0.1% Triton-
X100.
Immunohistochemistry was performed on mouse pan-
creas slices from wild type and TREK-1 invalidated mice
using goat antibodies against insulin (1/400, Santa Cruz
Technologies, sc-7838) and rabbit polyclonal anti-TREK1
(1/200, Millipore #AB5860). Briefly, adult male mice were
transcardially perfused with 4% paraformaldehyde in PBS
and then sacrificed. Pancreas was removed, postfixed in 4%
paraformaldehyde in PBS for 2 h at 4∘C, and transferred into
a 20% sucrose/PBS solution. After freezing of the pancreas
in isopentane, 35 𝜇m sections were cut in a cryostat. Sections
were stored at −20∘C. Labeling was performed as described
above for cells.
After two washes with PBS and one with water, coverslips
were mounted on glass slides with Mowiol for confocal
microscopy examination. Immunofluorescence of confocal
images was analysed using ImageJ 1.4.3.67 (WS Rasband,
National Institute of Health, https://imagej.nih.gov/ij/).
2.9. Intraperitoneal Glucose Tolerance Tests. Intraperitoneal
glucose tolerance tests (IPGTTs) were performed on mice
after an overnight (16 h) fast. 20min prior to injection of
glucose mice were injected (i.v.) with 100 𝜇l of a saline
solution (0.9% NaCl) in the absence or in the presence of
10−6MSPA (8 𝜇g/kg). Glucose administrationwas performed
via intraperitoneal injection (2 g/kg) in 6 to 8 mice for each
experimental group. Blood samples (100 𝜇l) were collected
from the tail vein before (basal glycemia) and after 10, 20, 30,
60, 90, and 120min following injection and glucose. Insulin
levels were then measured using an ELISA kit as described
above.
2.10. Statistical Analysis. Data are given as means ± SEM.
Statistical significance was evaluated with Student’s 𝑡-test
performed using GraphPad Prism.
3. Results
3.1. SPA Modulates Insulin Secretion in 𝛽-Cells. Previous
studies indicated the presence of sortilin in 𝛽-cell lines
and in mouse islets and of TREK-1 in 𝛽-TC3 cells [23,
28]. We therefore verified, using immunocytochemical and
immunohistological approaches, that the channel TREK-1
was also expressed in our models (islets and MIN6-B1 cells).
Figure 1(a) indicated that TREK-1 was expressed in mouse
islets visualized by insulin immunoreactivity staining. Con-
trol experiments performed on pancreatic slices from TREK-
1 KO mice confirmed the specificity of the antibody used
(Figure 1(b)). Figure 1(c) confirmed the expression of TREK-
1 in the insulin producing MIN6-B1 cells, particularly at the
level of plasmamembrane.The specificity of the TREK-1 anti-
bodies used was also confirmed by Western blot analyses of
islets proteins fromWT and KO-TREK-1 mice (Figure 1(d)).
The expression of both TREK-1 and sortilin (the pre-
cursor of the PE) in 𝛽-cells and in islets prompted us to
investigate the role of the PE related peptide SPA on insulin
secretion. Under basal conditions (5mM KCL, 2.8mM glu-
cose), incubation of isolated mouse islets and MIN6-B1 cells
with 0.1𝜇M of SPA for 45min did not modify the amount
of secreted insulin (Figures 2(a) and 2(c)). By contrast,
SPA potentiated KCl-induced insulin secretion both in islets
(from 19.2 ± 0.72 𝜇g/L to 27.47 ± 0.35 𝜇g/L, 𝑝 < 0.001)
(Figure 2(a)) and in MIN6-B1 cells (from 297.5 ± 2.92 𝜇g/L
to 427.7 ± 20.58 𝜇g/L, 𝑝 < 0.01) (Figure 2(b)). Interestingly,
SPA also increased the glucose-induced insulin secretion in
mice islets (from 37.8±0.73 𝜇g/L to 47.2±0.9 𝜇g/L, 𝑝 < 0.01)
(Figure 2(c)) and inMIN6-B1 cells (from 144.7±18.6 𝜇g/L to
241 ± 30 𝜇g/L, 𝑝 < 0.01) (Figure 2(d)).
3.2. SPA Modulates Resting Membrane Potential. The resting
membrane potential of neuronal cells (i.e., GABA neurons)
was known to be maintained in part by TREK-1 channels
on which SPA exerted a potent effect [29]. Furthermore,
in other cell types such as embryonic atrial myocytes [30]
and human osteoblasts [31], TREK-1 contributes to setting
the resting membrane potential. Interestingly, it was recently
reported that two members of the K
2
P family (TALK-1 and
TASK-1) are expressed in pancreatic islets [32, 33] in which
theymodulate electrical activity.We therefore postulated that
these background K+ channels could function as modulators
of 𝛽-cell excitability. To answer this question we tested the
effects of SPA on K+ current recorded on whole MIN6-B1
cell patch. As shown in Figure 3(a), TREK-1 current was
potentiated by 10 𝜇M arachidonic acid (AA) and application
of SPA (10−6M) inhibited the AA activated TREK-1 current.
This SPA effect was summarized in Figure 3(b) where the
difference of membrane potential of SPA-treated versus
control cells (𝐸mSPA − 𝐸mC) Δ𝐸m was 12.6 ± 2.0mV (𝑛 = 15,
𝑝 < 0.001). As a control we observed that glibenclamide
induced a depolarization up to −47.07 ± 2.33mV (𝑝 < 0.001)
(Δ𝐸m = 17 ± 2.3mV, 𝑝 < 0.001) (Figure 3(b)). We have
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Figure 1: TREK-1 channels are expressed in insulin-containing cells. Immunofluorescent labeling of TREK-1 channels endogenously
expressed inmouse pancreatic islets ((a) and (b)) andMIN6-B1 𝛽-cells (c). (a) Immunohistochemistry of mouse pancreas sections stained for
TREK-1 channels (Alexa-594) and insulin (Alexa-488) as described in Section 2. The merged image indicated colocalization of TREK-1 and
insulin (yellow arrows), some peripheral cells were labeled only with TREK-1 antibodies (white arrows). (b) Immunohistochemistry of mouse
pancreas sections from TREK-1 KO mice stained for TREK-1 channels (Alexa-594) and insulin (Alexa-488) clearly showed the absence of
TREK-1 labeling. (c) Immunocytochemistry ofMIN6-B1 cells was performed using anti-chromogranin A (labeling of secretory granules) and
anti-TREK-1 antibodies followed by anti-mouse Alexa-488 and anti-rabbit Alexa-594 secondary antibodies and DAPI for nucleus labeling.
Merged image showed the expression of TREK-1 at the plasma membrane (white arrows) (scale bar: 100 𝜇m). (d) Immunoblotting of
membrane homogenates from islets from WT and KO-TREK-1 mice, with anti-sortilin and anti-TREK-1, reveals a protein of 50 kDa for
TREK-1 and 95 kDa for sortilin, respectively.
also tested the SPA effect when added to glucose 20mM. As
expected, we observed a strong and robust depolarization
when the MIN6-B1 cells were incubated in the presence
of 20mM glucose, −60 ± 1.0mV (2mM glucose) versus
−48.71 ± 2.378mV (20mM glucose) (Figure 3(c)). Addition
of the GLP-1R agonist exendin4 (ex4) (10−7M) induced a
significant additive effect to reach −37.60 ± 2.50mV (𝑝 <
0.05). Interestingly, SPA effects were also additive to reach
−32 ± 1.826mV (𝑝 < 0.001) when coincubated with 20mM
glucose (Figure 3(c)).
3.3. Effect of SPA on Intracellular Calcium Content. After
recording of cultured MIN6-B1 𝛽-cells, we observed that,
as in INS1E 𝛽-cells [25], SPA (10−7M) induced an increase
in intracellular calcium level (ratio 340/380 value: 1.15 ±
0.16), which did not return at the basal level after withdrawal
(value: 0.46 ± 0.01 versus 0.69 ± 0.032, before and after SPA,
resp.) (Figure 4(a)). Since SPA increased the glucose-induced
insulin release like incretins, we compared the effect of ex4
with that of SPA. Ex4 induced an increase of intracellular
calcium level (value: 1.29 ± 0.1, 𝑝 < 0.001) as well as SPA
(1.30 ± 0.14, 𝑝 < 0.001) when compared with the basal level
(value: 0.61 ± 0.02). As controls, we measured the effect of
KCl (25mM) and glucose (20mM) on intracellular calcium
levels and obtained ratio values of 2.05±0.11 (𝑝 < 0.001) and
2.0 ± 0.11 (𝑝 < 0.001), respectively (Figure 4(b)). To verify the
involvement of intracellular cAMP on the SPA effect, we used
various concentrations of the stable analogue 8-Br-cAMP.
At low dose (5 𝜇M) the cAMP analogue increased calcium
levels from a ratio of 0.8 ± 0.03 to 1.25 ± 0.06 (𝑝 < 0.001)
(Figure 4(c)). However, addition of SPA (10−7M) enhanced
the signal values up to 1.87 ± 0.07 (𝑝 < 0.001 versus 5 𝜇M
8Br-cAMP alone) (Figure 4(c)). A higher dose of 8-Br-cAMP
(50 𝜇M) induced an increase of cytosolic calcium (from 0.75±
0.02 to 1.44 ± 0.14, 𝑝 < 0.001) that was not significantly
modified by addition of SPA (ratio of 1.39 ± 0.1) (Figure 4(d)).
Journal of Diabetes Research 5
KC
l5
m
M
KC
l5
m
M
 +
 S
PA
KC
l3
0
m
M
KC
l3
0
m
M
 +
 S
PA
∗∗∗
Islets
0
10
20
30
In
su
lin
 (𝜇
g/
L)
(a)
KC
l5
m
M
KC
l5
m
M
 +
 S
PA
KC
l3
0
m
M
KC
l3
0
m
M
 +
 S
PA
∗∗
MIN6-B1
0
100
200
300
400
500
In
su
lin
 (𝜇
g/
L)
(b)
∗∗
gl
u
2.
8
m
M
gl
u
2.
8
m
M
 +
 S
PA
gl
u
16
.7
m
M
gl
u
16
.7
m
M
 +
 S
PA
0
10
20
30
40
50
In
su
lin
 (𝜇
g/
L)
Islets
(c)
∗∗
gl
u
2.
8
m
M
gl
u
2.
8
m
M
 +
 S
PA
gl
u
16
.7
m
M
gl
u
16
.7
m
M
 +
 S
PA
0
100
200
300
In
su
lin
 (𝜇
g/
L)
MIN6-B1
(d)
Figure 2: Effects of SPA on insulin secretion from isolated islets and MIN6-B1 cells. Mouse islets (a) or MIN6-B1 cells (b) were incubated at
5mM (Cont) or stimulating concentration of 30mM KCl in the presence or in the absence of 10−7M SPA for 45min. Mouse islets (c) and
MIN6-B1 cells (d) were incubated under basal (2.8mM glucose) or under stimulating (16.7mM glucose) conditions in the presence or in the
absence of 10−7M of SPA for 45min. The amount of secreted insulin was normalized using the intracellular insulin concentration and was
expressed in 𝜇g/L. Each value represents the mean ± SEM from 3 independent experiments (∗∗𝑝 < 0.01 and ∗∗∗𝑝 < 0.001).
Interestingly, the PKA inhibitor H89 inhibited the ex4 effect
but not the SPA effect on calcium levels (Figure 4(e)). This
indicates that the action of SPA on intracellular calcium levels
is not dependent on PKA activity.
3.4. SPA Improves Plasma Insulin Level and Leads to Hypo-
glycemia in Mice. To investigate the role of SPA on glycemia
in mice, we challenged the action of i.v. injection of SPA
(100 𝜇L of 1 𝜇M, 8 𝜇g/kg) during the glucose tolerance test.
We followed the glucose serum concentration up to 120min
after i.p. injection of a high glucose solution (2 g/kg). In
control conditions (injection of 100 𝜇L saline), we observed
a typical response with a blood glucose concentration that
increased from the injection time up to 20–30min after
injection followed by the return to the basal level after 120min
(Figure 5(a)). In mice injected with SPA 20min before the
test, the increase in blood glucose concentration was smaller
to reach amaximal concentration of 332.6±31.26mg/dL (𝑛 =
7) compared to 404.1 ± 16.32mg/dL (𝑛 = 9) in the control
condition (𝑝 < 0.05) (Figure 5(a)) at 30min. At 60min, the
glycemia remained statistically lower in SPA-injected mice
(314.8± 26.04mg/dL, 𝑛 = 9 versus 229.3±20.55mg/dL, 𝑛 = 7,
𝑝 < 0.05) (Figure 5(a)). These differences were illustrated by
the smaller area under the curve (AUC) decreased by 28.46%
in the presence of SPA (20205 ± 1449 arbitrary unit (AU),
𝑛 = 9 for control versus 14455±2015AU, 𝑛 = 7 for SPA) (𝑝 <
0.05) (Figure 5(b)). In order to investigate the correlation
between the SPA-induced effect on glycemia and the amount
of insulin released in the blood, we measured both glucose
and insulin from blood samples collected before and 20min
after glucose injection. We confirmed that SPA significantly
decreased glycemia 20min after glucose injection (503 ±
12.9mg/dL (𝑛 = 13) for saline versus 450.4 ± 10.15mg/dL
(𝑛 = 13) for SPA) (𝑝 < 0.005) (Figure 5(c)). In parallel,
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Figure 3: TREK-1 channel current recorded from pancreatic MIN6-B1 cells. (a, b) Whole cell currents measured in MIN6-B1 cells. (a) 𝐼𝑉
curves and membrane potentials recorded after 1 h of incubation in control conditions (grey line), after stimulation of TREK-1 current by
10𝜇M of arachidonic acid (AA) (dark grey line) and in the presence of 1 𝜇M SPA (dark line). (b) Membrane potential mean values obtained
from these conditions; the difference between potential values was Δ𝑉m = 12.6 ± 2.02mV (𝑛 = 15) between control and SPA (
∗∗∗𝑝 < 0.001)
and Δ𝑉m = 17 ± 2.02mV (𝑛 = 15) between control and glibenclamide (
∗∗∗𝑝 < 0.001). (c) Membrane potential mean values obtained from
three different groups of cells incubated at low (2mM) and high (20mM) glucose concentrations in the absence or in the presence of 1𝜇M
ex4 or 1 𝜇M SPA. ∗𝑝 < 0.05 and ∗∗∗𝑝 < 0.001.
SPA significantly increased glucose-induced serum insulin
content (from 0.31 ± 0.03 𝜇g/L (𝑛 = 13) to 0.59 ± 0.13 𝜇g/L
(𝑛 = 12) (𝑝 = 0.029) (Figure 5(d)).
4. Discussion
The present work describes the effect of SPA in the regulation
of both glucose homeostasis and glucose-induced insulin
secretion. Although SPA displays an effect similar to those of
incretins, its mechanism of action is quite different since it is
not controlled by the intracellular levels of cAMP.
Developing safer drugs and drug candidates for the treat-
ment of diabetes is one of the major goals of the pharmaceu-
tical industry, and its importance has been intensified by the
withdrawal of many drugs from themarket due to side effects
and a decrease of new chemical entities introduced into the
market [34]. We initially developed SPA as a TREK-1 channel
blocker that could be used for the treatment against mood
disorders. In that perspective, we have established that SPA,
designed from an endogenous peptide, is a safer choice for a
new pharmacological concept due to its absence of toxicity
and long lasting central side effects [35, 36]. Since TREK-1 is
expressed in 𝛽-cells, we investigated the role of SPA in the
glucose homeostasis to verify that this compound does not
display any deleterious peripheral action [35]. In the present
work, we showed that SPA could have further interesting
functions in the regulation of glucose homeostasis.
Endocrine pancreatic islets can be compared in some
instance to neurons. Indeed, like neurons, 𝛽-cells secrete
insulin after depolarization of plasmamembrane upon stimu-
lation.The secretion process is controlled by ATP-dependent
potassium channels that are already a target in the devel-
opment of type 2 antidiabetic drugs. The background two-
pore potassium channel TREK-1 could also be an actor in the
regulation of membrane potential. In neurons, TREK-1 chan-
nels are important regulators in the signaling of serotonin (5-
HT) or gamma amino butyric acid (GABA), two neurotrans-
mitters involved in brain pathophysiology [37]. Therefore,
SPA, as a TREK-1 blocker, is able to improve brain functions
[29]. In the present work, we demonstrated that TREK-1
channels are expressed in endocrine pancreas (Figure 1) and
that SPA enhances stimulated insulin secretion both in islets
and in MIN6-B1 cells (Figure 2). Deciphering the effect of
SPA on 𝛽-cells by using the MIN6-B1 cell line, we observed
that the peptide is able to induce the depolarization of the
plasmamembrane with the same potency than glibenclamide
(a KATP channel blocker) and ex4 (a GLP1 receptor agonist)
(Figure 3). This plasma membrane depolarization likely
facilitates the exocytosis process through the enhancement
of intracellular calcium concentration (Figure 4). SPA does
not induce insulin secretion at low glucose concentration,
because it does not reach the threshold of depolarization
necessary to induce exocytosis. 𝛽-cell does not induce an
action potential even though more than 90% of the KATP
channels are closed [6]. We hypothesize that TREK-1 depo-
larization is not enough to induce a robust calcium entry.
As insulin secretion is a calcium dependent process, exo-
cytosis needs a stronger increase in calcium concentrations
to trigger fusion of insulin granules membrane with the
plasma membrane. Since SPA increases the glucose-induced
insulin secretion, we hypothesized that this peptide could
function like an incretin hormone. However, as expected,
H89 inhibits the effects of ex4 on calcium influx but not
those of SPA, indicating that its action is not mediated by
PKA and likely results only from the blocking of K+ currents.
We propose that TREK-1 currents can be blocked by SPA
or by PKA dependent phosphorylation. In this way, we
can hypothesize a direct blocking effect of SPA on TREK-1
Journal of Diabetes Research 7
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Figure 4: Effects of SPA on cytosolic calcium concentrations. Cytosolic calcium variations were measured using the Fura-2AM in the
mouse MIN6-B1 𝛽-cell line. Fura2-AM absorbance ratio (340/380) was given for the time point with the maximal signal. (a) At low glucose
concentration (5mM), SPA (10−7M) induced a significant cytosolic calcium rise (𝑛 = 18, 𝑝 < 0.01) that did not return to basal level after
washing out (𝑝 < 0.01). (b) Comparing SPA and ex4 effects, controls were performed using either KCl (25mM) or glucose (20mM) (𝑛 = 17).
(c) Preincubation of MIN6-B1 cells with 5mM 8Br-cAMP did not prevent the stimulating effect of SPA on calcium rise (𝑛 = 48). (d) When
MIN6-B1 cells were preincubated with 50mM 8Br-cAMP, SPA was not able to increase intracellular calcium (𝑛 = 12). (e) Preincubation
of MIN6-B1 cells in the presence of 1 𝜇M H89 significantly inhibited the ex4 effect but not that of SPA (𝑛 = 38). 𝑛 indicates the number of
responding cells in each of three experiments. Results are expressed as mean ± SEM; ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ns: nonsignificant.
activity whereas GLP1 agonists blocking action on these
channels are the consequence of their effects on PKA activa-
tion.
Finally, in vivo, we clearly observe an action of SPA
on glycemia since the glucose level is always lower in
mice treated with the peptide during IPGTT experiments.
During the glucose tolerance tests, SPA significantly increases
plasma insulin concentration indicating that the lower level of
glycemia is likely the consequence of insulin amount.
In conclusion, this work constitutes the first report on the
involvement of TREK-1 channels in the function of 𝛽-cells
particularly the secretion of insulin. Interestingly, the activity
of these channels can be modulated by SPA leading to an
incretin like action independent from the activation of PKA.
Therefore, this peptide could be the basis for the development
of new therapeutic strategies for the treatment of diabe-
tes.
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Figure 5: SPA modulates insulin secretion in mice. (a) IPGTT challenge (2 g/kg glucose i.p.) is performed onto two groups of C57Bl6 mice.
20 minutes before glucose injection, mice were injected (i.v.) with SPA (8𝜇g/kg) (square dots) or saline (round dots). Glycemia was measured
at time 0 (before injection) and 10, 20, 30, 60, 90, and 120 minutes after glucose injection, from blood samples collected from the caudal
vein tail (𝑛 = 9 for saline and 𝑛 = 7 for SPA). (b) The areas under curve (AUC) were calculated using GraphPad Prism from the mean of
individual AUC obtained for each mouse. (c) Glycemia was measured from blood samples collected before i.v. injection of SPA (𝑛 = 12) or
saline (𝑛 = 13) (𝑡0) and 20 minutes after i.p. glucose injection (𝑡20). (d) Plasma insulin concentration was measured from the same blood
samples as above (∗∗𝑝 < 0.01, ∗𝑝 < 0.05).
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